Blandini, Fabio <br/><br/>
New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.  [electronic resource] 

 -  Expert opinion on investigational drugs  Feb 2012 
 - 153-68 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7658 
<br/><br/><label>Standard No.: </label>10.1517/13543784.2012.651457  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antiparkinson Agents--adverse effects<br/>Dyskinesias--drug therapy<br/>Excitatory Amino Acid Antagonists--therapeutic use<br/>Humans<br/>Levodopa--adverse effects<br/>Parkinson Disease--drug therapy<br/>Purinergic P1 Receptor Antagonists--therapeutic use<br/>Receptors, Glutamate--metabolism<br/>Receptors, Purinergic P1--metabolism